Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis-Reference-Cited by-同舟云学术

Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis

Published:2016-08 Issue:8 Volume:74 Page:650-652
ISSN:0004-282X
Container-title:Arquivos de Neuro-Psiquiatria
language:
Short-container-title:Arq. Neuro-Psiquiatr.

Author:

Fragoso Yara Dadalti¹,Alves-Leon Soniza Vieira²,Becker Jefferson³,Brooks Joseph Bruno Bidin¹,Correa Eber Castro⁴,Damasceno Alfredo⁵,Gama Paulo Diniz da⁶,Gama Rodrigo Assad da⁶,Matta Andre Palma da Cunha⁷,Maciel Ernane Pires⁸,Winckler Thereza Cristina d’Avila⁹

Affiliation:

1. Universidade Metropolitana de Santos, Brasil

2. Universidade Federal do Estado do Rio de Janeiro, Brasil

3. Pontifícia Universidade Católica do Rio Grande do Sul, Brasil

4. Clinica de Neurologia e Endocrinologia, Brasil

5. Universidade Estadual de Campinas, Brasil

6. Pontifícia Universidade Católica Sorocaba, Brasil

7. Universidade Federal Fluminense, Brasil

8. Hospital de Base do Distrito Federal, Brasil

9. Universidade Positivo, Brasil

Abstract

ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.

Publisher

FapUNIFESP (SciELO)

Subject

Neurology,Clinical Neurology

Link

http://www.scielo.br/pdf/anp/v74n8/0004-282X-anp-74-08-0650.pdf

Reference10 articles.

1. Natalizumab therapy for multiple sclerosis;Derfuss T;Semin Neurol,2013

2. Natalizumab: risk stratification of individual patients with multiple sclerosis;Tur C;CNS Drugs,2014

3. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab;Baumgartner A;Int J Neurosci,2012

4. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation;Capobianco M;Eur J Neurol,2015

5. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy;Stüve O;Neurology,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Fingolimod Compared to Placebo in the Treatment of Relapsing Multiple Sclerosis: A Systematic Review and Meta-analysis Study;Qom Univ Med Sci J;2021-02-01

2. A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis;Autoimmunity Reviews;2019-03

3. Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosis;Multiple Sclerosis and Demyelinating Disorders;2017-06-26

4. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events;Acta Neurologica Belgica;2017-05-20

5. Sometimes less is more in multiple sclerosis drug switching;Arquivos de Neuro-Psiquiatria;2016-08